News
When it comes to weight loss, there are a number of tried and true lifestyle changes you can make to help you along the way.
Soon after last month’s end of her turbulent two-year run as CEO of X (formerly Twitter), Linda Yaccarino has landed another ...
GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...
Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss space.
Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...
The eMed Population Health digital health platform announced Tuesday that former X Chief Executive Officer Linda Yaccarino ...
After stepping down from X in July, Yaccarino is taking the CEO job at eMed Population Health, which makes a digital health platform for managing GLP-1 weight loss drugs. [Link: eMed® Population ...
The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...
1h
HealthDay on MSNGLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic NeuropathyFor older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...
Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...
A Massachusetts biotech working on a class of medicines called circular RNA therapeutics beat out companies from around the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results